GlassScriptPhysician profile
Brian Michael Capogna
NPI 1316207053
$6,702.87
in general payments reported to CMS, 2019-2025
19 companies · $28.83 in 2025
The $28.83 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $819 · 2020: $23.60 · 2021: $2,758 · 2022: $229 · 2023: $192 · 2024: $2,652 · 2025: $28.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,118 · Food and Beverage: $755.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,117.84 |
| Food and Beverage | $755.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $2,459.42 | 2019-2024 | Real Intelligence |
| Gotham Surgical Solutions & Devices, INC. | $2,400.00 | 2021 | |
| Stryker Corporation | $578.18 | 2019-2024 | Gamma, Variax |
| Bioventus LLC | $464.18 | 2019-2025 | Durolane, Durolane |
| Hitachi Healthcare Americas Corp. | $140.55 | 2019 | |
| Zimmer Biomet Holdings, INC. | $124.90 | 2019 | |
| Joint Restoration Foundation, INC. | $80.40 | 2019 | |
| Ferring Pharmaceuticals INC. | $75.99 | 2020-2023 | Euflexxa |
| Endo Pharmaceuticals INC. | $73.49 | 2019-2023 | Xiaflex |
| Depuy Synthes Sales INC. | $53.46 | 2019 | |
| Orthofix Medical, INC. | $48.98 | 2019 | |
| Vericel Corporation | $42.74 | 2022 | |
| Eagle Pharmaceuticals, INC. | $40.79 | 2023 | |
| Djo, LLC | $40.12 | 2024 | Cmf |
| Cumberland Pharmaceuticals, INC. | $21.36 | 2024 | Caldolor |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $17.71 | 2021 | |
| Biomarin Pharmaceutical INC. | $16.77 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.24 | 2019 | |
| Nevro Corp. | $11.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Capogna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.